Syncromune, Inc., a clinical-stage biopharmaceutical company, will present Phase 1 clinical data for its novel SYNC-T Therapy SV-102 at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting 2025. The presentation, scheduled for May 31 at McCormick Place in Chicago, will showcase results from the company's innovative approach to treating metastatic castration-resistant prostate cancer (mCRPC).
Dr. Ricky T. Tong, Clinical Assistant Professor at Lankenau Institute for Medical Research, will present the data during the "Developmental Therapeutics - Immunotherapy" session. The presentation, titled "Clinical responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC)," will highlight the therapy's potential impact on the treatment landscape for this challenging disease.
A Novel Approach to Solid Tumor Immunotherapy
SYNC-T represents a potentially first-in-class platform immunotherapy designed to address major unmet needs in treating metastatic solid tumors. The therapy employs a unique "synchronization of location" approach that brings together three critical components for effective immune response: tumor antigens, immune cells, and Syncromune's proprietary multi-target biologic drug.
"Our approach is designed to unite these critical components in the tumor microenvironment and lymphatics where the immune system optimally functions," explained a company representative. "This synchronization potentially enables more effective T cell activation against the cancer."
Innovative Delivery Mechanism
What distinguishes SYNC-T is its novel proprietary device delivery system optimized for combination drug/device immunotherapy. The system works through a two-step process:
- First, it lyses a portion of the target tumor, rupturing cancer cells and releasing tumor antigens into the tumor microenvironment (TME)
- Next, it facilitates the direct infusion of Syncromune's multi-target biologic drug into the tumor
This approach aims to promote in situ immune activation while simultaneously combating immune suppression. By minimizing systemic drug exposure, the therapy potentially offers improved safety compared to traditional systemic immunotherapies.
Addressing the Challenge of Metastatic Prostate Cancer
Metastatic castration-resistant prostate cancer represents a significant treatment challenge with limited effective options once the disease progresses beyond hormone therapy. Current immunotherapies have shown limited efficacy in prostate cancer compared to other solid tumors.
SYNC-T Therapy SV-102, Syncromune's lead candidate, is specifically being developed for mCRPC patients. Following the Phase 1 trial, the therapy has advanced to a U.S. multicenter Phase 2a trial, known as the Legion 100 trial.
Looking Toward Future Applications
While initially focused on mCRPC, Syncromune's platform technology could potentially be applied to other solid tumor types. The in situ personalized cancer vaccination approach aims to activate T cells that can recognize and attack cancer throughout the body and potentially establish immune memory against the patient's specific cancer antigens.
The ASCO presentation will provide the oncology community with the first detailed look at the clinical data from the Phase 1 trial, offering insights into safety, tolerability, and preliminary efficacy signals. Full details of the results are expected to be disclosed during the presentation.
For patients and clinicians interested in the ongoing Phase 2a trial, more information is available at www.legion100trial.com.
